Trial Profile
A Phase 1-2, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 May 2022
Price :
$35
*
At a glance
- Drugs Namodenoson (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Can-Fite BioPharma
- 25 Oct 2018 According to a Can-Fite Biopharma media release, data from this trial will be presented at The NYC Oncology Investor Conference 2018 taking place on October 30-31. (https://www.nyconcologyconference.com
- 28 Aug 2013 Data from this study were published in The Oncologist in January 2013, and will be presented at the 18th World Congress on Advances in Oncology, according to a Can-Fite BioPharma media release.
- 01 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.